Exporting Drug Screening Cups to Costa Rica: Market Entry
This paper analyzes the market entry strategy for Pharma Plus, a hypothetical pharmaceutical company seeking to export FDA-approved drug screening cups ("Pharma Drug Screeners") to Costa Rica. Drawing on the U.S. Department of Commerce Country Commercial Guide, the paper evaluates Costa Rica's macroeconomic environment, trade incentives under CAFTA-DR, and regulatory landscape for medical devices. It examines product adaptation requirements, emerging-market expansion sequencing, special service arrangements, decision-making structures, and the relative merits of foreign direct investment, joint ventures, and direct exporting. The paper also identifies major competitors operating in Costa Rica's medical equipment market and outlines a branding rationale for the company's generic brand name strategy.
- Introduction and Country Overview: Background on Costa Rica's economy and product
- Rationale for Entering the Costa Rican Market: Trade agreements, incentives, and market opportunity
- Product Adaptation Requirements: Licensing, labeling, and distribution partner needs
- Emerging Markets Entry Strategy: Phased expansion across Central and Latin America
- Special Services, Decision Making, and Investment Forms: Operations, management structure, and FDI vs. export
- Competitors and Branding in Costa Rica: Key rivals and generic brand name rationale
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Grounds every strategic recommendation in a specific data point — GDP figures, FDI growth rates, CAFTA-DR duty exemptions, and the WEF competitive index — giving the argument an empirical backbone rather than relying on generalizations.
- Follows a clear, step-by-step business-plan logic: country overview → rationale → product changes → entry sequencing → operational requirements → investment modes → competitive landscape, making it easy to follow as a decision-making document.
- Compares multiple investment modes (FDI, joint venture, and export) and provides a cost-benefit justification for the chosen approach, demonstrating analytical rather than purely descriptive reasoning.
Key academic technique demonstrated
The paper demonstrates applied market analysis by synthesizing government trade guidance (U.S. DOC Country Commercial Guide), macroeconomic data (IMF), and academic literature on emerging markets and branding into a unified strategic recommendation. This cross-source synthesis, anchored by a specific product and destination, shows how to move from secondary research to actionable business conclusions.
Structure breakdown
The paper opens with a general framing of international market entry modes, then narrows to the chosen destination and product. Subsequent sections address the destination country's environment, product changes, market expansion sequencing, operational logistics, investment form selection, and competitive context. The final section ties branding decisions back to competitive positioning, closing the strategic argument cohesively.
Introduction and Country Overview
For any company considering international operations, there are many alternatives to choose from when selecting a mode of entry into foreign markets. While foreign direct investment (FDI) is considered the most pervasive entry mode used by transnational corporations, smaller firms often prefer partnering with a local firm or exporting their merchandise to the destination country. By exporting and partnering with local firms, small and medium enterprises (SMEs) can better understand the political, economic, and regulatory environment of the destination country.
As a starting point, the U.S. Department of Commerce (DOC) provides effective guidance for U.S. firms investing abroad. The DOC website publishes a "Country Commercial Guide" for each country, making it easier for domestic investors to identify potentially lucrative industry sectors abroad. This paper selects Costa Rica as the destination country for the marketing and sales activities of a clinical-pharmaceutical product called "drug testers" — FDA-approved drug testing cups. Using the DOC Country Commercial Guide, the following sections offer a comprehensive analysis of the destination country's market.
Company name: Pharma Plus (assumed)
Product category: Drug Screening Cups
Product name: Pharma Drug Screeners
Costa Rica is situated in Central America and is the second-largest economy of the region, with a GDP of $48.843 billion in 2011 and $58.6 billion in 2012 (IMF, 2012). Average GDP growth was 4–5% in 2012, and the country carried out an estimated $16.2 billion in two-way trade with the U.S. in 2011 (Export.gov, 2012). FDI increased by 8% in 2012, and commercial banks charged an annual interest rate of 16%. Costa Rica's Transparency International (TI) corruption index stands at 5.3. The Costa Rican economy is services-based, with services comprising 72% of GDP, while agriculture and industry account for 7% and 21%, respectively.
Rationale for Entering the Costa Rican Market
The primary rationale for exporting Pharma Plus products to Costa Rica is the country's close geographical proximity to the U.S. and Canada, the two countries where the company already operates. There are also trade-specific benefits available to exporting firms under the Central America Free Trade Agreement–Dominican Republic (CAFTA-DR). Under this agreement, 80% of non-agricultural duties on our product will be waived. Pharma Plus can also participate in all government bids without being discriminated against on the basis of country of origin.
The U.S. Department of State (Export.gov) recommends that U.S. companies invest in drugs, pharmaceuticals, and medical and dental equipment in Costa Rica. The country's Global Competitive Index is also favorable, ranked 39 out of 139 countries as announced by the World Economic Forum (WEF). The healthy business environment is demonstrated by the presence of large U.S. companies such as Intel, HP, and P&G, all of which have started operations in Costa Rica with several hundred employees. Institutionalized business incentives — including preferred trade partnerships and the Metro Free Zone of Heredia, where Pharma Plus plans to open its export office — further support market entry.
The increasing number of private hospitals and medical centers underscores why this potentially lucrative Central American market should not be overlooked. Currently, the Costa Rican Social Security System (Caja Costarricense de Seguro Social: CCSS or CAJA) purchases approximately 90% of all medical equipment in Costa Rica. However, the government is under significant public pressure to replace obsolete medical equipment with competitive alternatives available from U.S. companies.
The commercial guide also reveals that medical tourism to Costa Rica from the U.S. and Canada is substantial, with visitors seeking orthopedics (hip, shoulder, and knee replacement), bariatric and gastric surgery, dermatology (laser skin and wrinkle removal), plastic surgery (liposuction and face lifting), and dentistry. The influx of medical tourists increased in 2011 (U.S. Commercial Service, 2013, p. 31). The total market size for the medical and dental equipment industry has grown considerably in Costa Rica, along with imports of medical equipment from the U.S. Taken together, healthy macroeconomic prospects, trade liberalization, business incentives, and the recommendation of the U.S. Commercial Service provide a strong case for exporting Pharma Plus drug testing cups to Costa Rica.
Product Adaptation Requirements
In principle, Pharma Plus products will require only minor procedural changes before entering the Costa Rican market. The main hurdle in exporting medical and health-related equipment is typically the acquisition of licenses; however, since July 2011, the Costa Rican Ministry of Health (MOH) has exempted U.S. medical devices and equipment from obtaining separate MOH approval or licenses. Drugs and equipment already approved by the U.S. Food and Drug Administration (FDA) may be sold and distributed directly in the Costa Rican market. Labeling and packaging changes are also not required by local health regulators. There is no language barrier for the product itself, as the "Drug Testers" labels and instruction manuals will remain in English.
The one visibly challenging task will be selecting an appropriate local partner to act as distribution agent for the drug testing cups. Since the product is primarily used in clinical laboratories, specialized healthcare hospitals, and operating theatres, Pharma Plus will need to establish business-level relationships with potential distributors as well as end customers.
References
Dawar, N. N., & Chattopadhyay, A. (2002). Rethinking marketing programs for emerging markets. Long-Range Planning, 35(5), 457–474. Retrieved from http://deepblue.lib.umich.edu/bitstream/handle/2027.42/39704/wp320.pdf
Export.gov. (2012). Country Commercial Guide Summary. Retrieved from http://export.gov/costarica/doingbusinessincostarica/index.asp
IMF. (2012). Report for selected countries and subjects. International Monetary Fund. Retrieved from http://www.imf.org/external/pubs/ft/weo/2012/01/weodata/weorept.aspx
Kohli, C. S., Harich, K. R., & Leuthesser, L. (2005). Creating brand identity: A study of evaluation of new brand names. Journal of Business Research, 58(11), 1506–1515.
Smith, R. D., Chanda, R., & Tangcharoensathien, V. (2009). Trade in health-related services. The Lancet, 373(9663), 593–601.
U.S. Commercial Service. (2013). 2013 Country Commercial Guide for U.S. companies. U.S. Department of Commerce. Retrieved from
Create your account
Always verify citation format against your institution’s current style guide requirements.